CraniUS Therapeutics Closes $20 Million Series B Round to Advance NeuroPASS™ Platform Towards Future Commercialization
Enabling Direct Therapeutic Access Beyond the Blood-Brain Barrier BALTIMORE, Jan. 28, 2026 /PRNewswire/ — CraniUS Therapeutics LLC, a privately held neurotechnology company, today announced it has raised $20 million in Series B financing to accelerate development of…